3-(4-oxo-4,5,6,7-tetrahydro-1H-indol-3-yl)propanoic acid | 218129-12-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(4-oxo-4,5,6,7-tetrahydro-1H-indol-3-yl)propanoic acid
• 英文别名: 3-(2'-carboxyethyl)-4,5,6,7-tetrahydroindol-4-one；3-(4-oxo-4,5,6,7,tetrahydro)-1H-indol-3-yl-propionic acid；3-(4-oxo-4,5,6,7,tetrahydro-1H-indol-3-yl)-propionic acid；3-(4-oxo-4,5,6,7-tetrahydro-1H-indol-3-yl)propionic acid；3-carboxyethyl-4-oxo-4,5,6,7-tetrahydro-1H-indole；3-(4-oxo-1,5,6,7-tetrahydroindol-3-yl)propanoic acid
• CAS: 218129-12-5
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: DLNQZPJCLLSKPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-oxo-4,5,6,7-tetrahydro-1H-indol-3-yl)propanoic acid 在 lithium aluminium tetrahydride 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 dimethyl-[3-(4,5,6,7-tetrahydro-1H-indol-3-yl)-propyl]-amine
  参考文献：
  名称：

  Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase

  摘要：

  A novel series of substituted 3-[3-(aminopropyl)-4,5,6,7-tetrahydro-1H-indol-2-ylmethylene]-1,3-dihydro-indole-2-ones was discovered as potent inhibitors of the non-receptor tyrosine kinase Src and Yes. A structure-activity relationship was developed in order to optimize their potency and selectivity. Syntheses of these compounds are also described herein. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.069
• 作为产物：
  描述：

  5-氨基乙酰丙酸盐酸盐 、 1,2-环己二酮 在 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 以67%的产率得到3-(4-oxo-4,5,6,7-tetrahydro-1H-indol-3-yl)propanoic acid
  参考文献：
  名称：

  3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors

  摘要：

  本发明涉及抑制激酶的某些3-(4,5,6,7-四氢吲哚-2-基甲基)-2-吲哚酮衍生物，特别是Src激酶。还公开了包括这些化合物的药物组合物、利用包括这些化合物的药物组合物治疗激酶介导的疾病的方法，以及它们的制备方法。

  公开号：

  US20030119819A1

文献信息

• 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
  申请人：SUGEN Inc.

  公开号：US20040204407A1

  公开（公告）日：2004-10-14

  The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及调节蛋白激酶（“PKs”）活性的5-磺胺基取代吲哚酮。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。包括这些化合物的药物组合物、利用包括这些化合物的药物组合物治疗疾病的方法以及它们的制备方法也被披露。
• Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
  申请人：Sugen, Inc.

  公开号：US20040266843A1

  公开（公告）日：2004-12-30

  The present invention relates generally to the field of radiosensitizing agents which are capable of enhancing radiotherapy by inhibiting DNA-PK (DNA-protein kinase). In particular, it relates to sulfonamide substituted indolinones which inhibit DNA-PK.

  本发明通常涉及放射增敏剂领域，这些放射增敏剂能够通过抑制DNA-PK（DNA-蛋白激酶）来增强放射疗法。具体而言，涉及抑制DNA-PK的磺胺基取代吲哚酮。
• Indolinone Compounds as Kinase Inhibitors
  申请人：Huang Jiann-Jyh

  公开号：US20100179146A1

  公开（公告）日：2010-07-15

  Indolinone compounds of formula (I) or (II): wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and n are defined herein. Also disclosed are methods for decreasing the activity of a protein kinase and for treating a protein kinase-related disease, such as cancer, with these compounds.

  式(I)或(II)的吲哚酮化合物：其中A，R1，R2，R3，R4，R5，R6，R7和n在此定义。还公开了使用这些化合物降低蛋白激酶活性和治疗蛋白激酶相关疾病，如癌症的方法。
• Some Reactions of 5-Aminolevulinic Acid with Cyclic β-Diketones
  作者：Elaine H. Brown、Anthony R. Butler

  DOI：10.1039/a802819b

  日期：——

  5-Aminolevulinic acid reacts, under acidic conditions, with cyclohexane-1,3-diones to give 3-(2′-carboxyethyl)tetrahydroindol-4-ones which were characterised, in part, by 2D NMR spectroscopy.

  5-氨基乙酰丙酸在酸性条件下与环己烷-1,3-二酮反应生成 3-(2'-羧乙基)四氢吲哚-4-酮，部分通过 2D NMR 光谱表征。
• 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
  申请人：SUGEN, INC.

  公开号：US20040266855A1

  公开（公告）日：2004-12-30

  The present invention relates to certain 3-(4,5,6,7-tetrahydroindol-2-yl-methylidene)-2-indolinone derivatives that inhibit kinases, in particular Src kinase. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.

  本发明涉及某些3-(4,5,6,7-四氢吲哚-2-基甲基)-2-吲哚酮衍生物，其抑制激酶，特别是Src激酶。本发明还公开了包含这些化合物的药物组合物、利用包含这些化合物的药物组合物治疗激酶介导的疾病的方法，以及制备这些化合物的方法。